Vusolimogene oderparepvec
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Vusolimogene oderparepvec |
| Trade Name | Tudriqev |
| Synonyms | vusolimogene oderparepvec-wtpg|RP1|HSV-1 Engineered RP1 |
| Drug Descriptions |
Tudriqev (vusolimogene oderparepvec) is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain that expresses a fusogenic glycoprotein (GALV-GP-R-) and GM-CSF, which potentially induces an anti-tumor immune response and tumor cell lysis (Cancer Res (2024) 84 (7_Supplement): CT003, NCI Drug Dictionary). Tudriqev (vusolimogene oderparepvec) is FDA-approved for use in combination with nivolumab for patients with unresectable advanced cutaneous melanoma who have progressed on a PD-1 inhibitor therapy (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C158074 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
CKB BOOST